Scroll
To Top

Archives for: November 1st, 2022

Highlights from the 2022 NORD Breakthrough Summit

Written by Rohan Narayanan on November 1, 2022
Three people stand in front of the NORD logo - Peter Saltonstall, Robert Califf, and Pam Gavin

Last month, more than 830 enthusiastic attendees gathered in-person (and many more virtually) for the 2022 NORD Rare Diseases and Orphan Products Breakthrough Summit to address and take action on the opportunities and challenges facing the rare disease community. Here are a few highlights:

FDA Commissioner Presents Keynote Address

FDA Commissioner Robert… Read More

NORD Issues Statement on FDA’s New Associate Director for Rare Diseases

Written by Jennifer Huron on July 23, 2015

The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), on today’s announcement that Jonathan C. Goldsmith, MD, FACP, will lead the Rare Diseases Program in the Center for Drug Evaluation and Research (CDER) Office of New Drugs at the… Read More

FDA Creates New Web-Based Educational Tool About the Agency

Written by Mary Dunkle on February 28, 2014

The Food and Drug Administration’s Office of Orphan Products Development (OOPD), in collaboration with the FDA Center for Drug Evaluation and Research (CDER), has launched a web-based educational tool for rare disease patients, advocacy groups, researchers and industry on various FDA-related topics. Read More